Navigation Links
Johnson & Johnson Reports 2008 Third-Quarter Results:
Date:10/14/2008

leptic and a treatment for the prevention of migraine headaches; and RISPERDAL CONSTA, an antipsychotic medication. Sales results of RISPERDAL were negatively impacted by generic competition.

During the quarter, the European Commission granted marketing authorization for INTELENCE, a next generation non-nucleoside reverse transcriptase inhibitor; DORIBAX, an antibiotic used as a treatment for complicated urinary tract infections, complicated intra-abdominal infections, and nosocomial pneumonia including ventilator-associated pneumonia; and for VELCADE, in combination with melphalan and prednisone, for the treatment of patients with previously untreated multiple myeloma. In addition, the Company submitted a New Drug Application to the U.S. Food and Drug Administration (FDA) for rivaroxaban, an investigational, oral, once daily anticoagulant for the prevention of deep vein thrombosis and pulmonary embolism in patients undergoing hip or knee replacement surgery. The Company also submitted a supplemental new drug application to the FDA for the combination of DOXIL and Taxotere(R) for the treatment of women with advanced breast cancer who have received prior anthracycline treatment. In July, the FDA granted pediatric exclusivity for TOPAMAX extending the marketing exclusivity through March 2009.

About Johnson & Johnson

Caring for the world, one person at a time...inspires and unites the people of Johnson & Johnson. We embrace research and science - bringing innovative ideas, products and services to advance the health and well-being of people. Our 119,400 employees at more than 250 Johnson & Johnson companies work with partners in health care to touch the lives of over a billion people every day, throughout the world.

* Net earnings and diluted earnings per share excluding special items, such as after-tax in-process research and development charges and restructuring charges, are non-GAAP financial measures and should not be considered replacem
'/>"/>

SOURCE Johnson & Johnson
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21

Related medicine news :

1. Johnson & Johnson to Participate in Bear Stearns 20th Annual Healthcare Conference
2. Draxis Health selected by Johnson and Johnson Consumer Companies, Inc. for major contract manufacturing relationship
3. Johnson & Johnson Campaign for Nursings Future Joins With AACN to Offer New Minority Nurse Faculty Scholars Program
4. Trust for Americas Health Receives $7.6 Million Grant from the Robert Wood Johnson Foundation to Advance the Quality and Impact of the Public Health System
5. Deane F. Johnson Center for Neurotherapeutics to Launch First Mobile Medical Unit on October 4th
6. Johnson & Johnson Tops Annual Pharmaceutical Company Rankings in a New Report From Industry-Leading Publication Scrip
7. Independence Technology, A Johnson & Johnson Company, Renews Its Contract With Creative Technology Services
8. Johnson & Johnson Launches Global Diabetes Institute to Provide State-of-The- Art Education, Training to Health Professionals
9. Robert Wood Johnson Foundation Announces $15.6 Million Grant to Apply Power of the Archimedes Model to Critical Health Care Decisions
10. UAN Mourns Passing of President Cheryl L. Johnson, RN
11. Johnson & Johnson Pharmaceutical Research & Development Submits New Drug Application for Paliperidone Palmitate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/29/2015)... ... June 29, 2015 , ... Scientists from ... to build nearly complete genomes by combining high-throughput DNA sequencing with genome mapping. ... for their association with human disease, but previously difficult to detect. The study ...
(Date:6/29/2015)... ... June 29, 2015 , ... Assurex Health, a ... certain neuropsychiatric and chronic pain conditions, has announced appointments to three key leadership ... Peter Donato, Senior Vice President, Chief Financial Officer; Craig S. Lewis, Senior Vice ...
(Date:6/29/2015)... ... June 29, 2015 , ... OR Manager announced Monday the launch of an ... well as a redesigned logo and weekly eLetter. The website contains the same informational ... and easier to navigate. , In addition to a refreshed look, http://www.ormanager.com ...
(Date:6/29/2015)... ... 29, 2015 , ... Bionops Laboratories has released the first ... consumers. , The specialized eye health formulation contains a variety of ingredients to ... addition to Citicoline (Cognizin®), Biomacula provides necessary doses of Vitamin E, Glutathione, Resveratrol, ...
(Date:6/29/2015)... ... June 29, 2015 , ... FACE is proud to be one of ... reduction of the double chin and redefining of the jawline. Excess fat under ... older and heavier causing the person distress and poor self-image. , Kybella was produced ...
Breaking Medicine News(10 mins):Health News:Mount Sinai Scientists Develop New Approach for More Accurate and Comprehensive Whole Genome Assembly, Variant Discovery and Interpretation 2Health News:Mount Sinai Scientists Develop New Approach for More Accurate and Comprehensive Whole Genome Assembly, Variant Discovery and Interpretation 3Health News:Mount Sinai Scientists Develop New Approach for More Accurate and Comprehensive Whole Genome Assembly, Variant Discovery and Interpretation 4Health News:Assurex Health Names Executives to Posts as CFO, CMO and VP/Clinical Operations 2Health News:Assurex Health Names Executives to Posts as CFO, CMO and VP/Clinical Operations 3Health News:OR Manager Launches New Website 2Health News:Bionops Laboratory Releases Biomacula, the First French Product with Citicoline (Cognizin®) 2Health News:Bionops Laboratory Releases Biomacula, the First French Product with Citicoline (Cognizin®) 3Health News:FACE Detroit Skin and Wellness Clinic Introduces Newly FDA Approved Kybella for the elimination of the Double Chin. 2
... ... Best Nursing Homes” List , ... Tucson, Ariz. (Vocus) February 2, 2010 -- A Tucson retirement community’s health ... by U.S. News and World Report. The designation will appear in the national magazine’s ...
... , INDIANAPOLIS , Feb. 2 ... senior management is scheduled to present at the UBS 20th Annual ... 8:00 a.m. Eastern Standard Time .   , All interested ... by visiting www.wellpoint.com and selecting the "Investor ...
... the University of Pennsylvania School of Medicine have found ... a toxic form of the same protein. The protein, ... that are the hallmarks of Parkinson,s disease, Alzheimer,s disease, ... molecular link between the presence of inclusions and neuronal ...
... study found , TUESDAY, Feb. 2 (HealthDay News) -- ... who are at risk for kidney failure and associated problems, ... in the Feb. 3 issue of the Journal of ... for protein levels in urine (proteinuria) be incorporated into upcoming ...
... , SOMERSET, N.J. , Feb. 2 ... logistical staffing provider serving the Federal Government, today announced that it ... the Company has regained compliance with the $1.00 per ... Nasdaq Capital Market, pursuant to the Nasdaq Marketplace Rules. In the ...
... link between MMR vaccine, developmental disorder , TUESDAY, ... journal The Lancet on Tuesday formally retracted ... mumps and rubella vaccine to autism and gastrointestinal problems. ... 1998, set off a worldwide furor, with many researchers ...
Cached Medicine News:Health News:U.S. News & World Report Ranks Sonora at Splendido Among Top in Nation 2Health News:WellPoint Announces Appearance at Upcoming Conference 2Health News:WellPoint Announces Appearance at Upcoming Conference 3Health News:3 brain diseases linked by toxic form of same neural protein 2Health News:Protein Levels in Urine Help Predict Kidney Function 2Health News:Protein Levels in Urine Help Predict Kidney Function 3Health News:TeamStaff Regains Compliance with Nasdaq $1.00 Minimum Bid Rule 2Health News:TeamStaff Regains Compliance with Nasdaq $1.00 Minimum Bid Rule 3Health News:Controversial Autism Study Retracted by Medical Journal 2Health News:Controversial Autism Study Retracted by Medical Journal 3Health News:Controversial Autism Study Retracted by Medical Journal 4
(Date:6/29/2015)... ZIONA, Israel , June 29, ... BVXV, TASE: BVXV) today announced positive preliminary results from ... candidate for a universal influenza vaccine. In this trial, ... of 50 to 65, followed by an administration of ... later. M-001 was found to be safe and well ...
(Date:6/29/2015)... Calif. , June 29, 2015  Isis Pharmaceuticals, ... has been added to the Russell 1000 Index, effective ... performance of the large-cap segment of the U.S. equity ... Index and includes approximately 1000 of the largest securities ... current index membership. "We are pleased to ...
(Date:6/29/2015)... Calif. , June 29, 2015  Arbor ... medical workstation lineup. The high-powered, multi-functional M2150 ... generation Intel® Haswell Core i5-4402E 1.6 ... provide significant data processing and computing performance. Integrated ... making the unit well suited for graphics-intense applications ...
Breaking Medicine Technology:BiondVax Presents BVX-006 Preliminary Phase II Results: the Universal Flu Vaccine at Higher Doses is Safe and Improves Immunogenicity in Older Adults 2BiondVax Presents BVX-006 Preliminary Phase II Results: the Universal Flu Vaccine at Higher Doses is Safe and Improves Immunogenicity in Older Adults 3ISIS Pharmaceuticals Promoted to the Large-Cap Russell 1000 Index 2ISIS Pharmaceuticals Promoted to the Large-Cap Russell 1000 Index 3Arbor Solution Introduces Multi-Function Medical Workstation with Large 21.5" True Flat Touch Screen 2Arbor Solution Introduces Multi-Function Medical Workstation with Large 21.5" True Flat Touch Screen 3
... , CHEYENNE, Wyo., Aug. 24 The ... of its Pay-for-Participation (P4P) program, a component of its innovative ... collaboration between the practitioner community and the Wyoming EqualityCare (EC) ... Wyoming Medicaid members. , , (Logo: ...
... Curemark Founder and CEO Dr. Joan Fallon delivered the ... Conference at Harvard Medical School on July 14th. , ... conclave is particularly significant, since epigenetics is the study of ... in the DNA sequence. Presenters at the session showcased many ...
Cached Medicine Technology:Wyoming Department of Health's Pay-for-Participation Program Reports Positive Clinical Outcomes 2Wyoming Department of Health's Pay-for-Participation Program Reports Positive Clinical Outcomes 3Curemark CEO Presents at Epigenomics Conference 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: